AV
AVTX.US Avalo Therapeutics Inc
- Market cap
- USD 449M
- P/E
- -
- P/B
- 1.02x
- ROE
- -22.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AVTX.US undervalued?
Graham numberThe Graham number of Avalo Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Avalo Therapeutics Inc fundamental analysis
No fundamental analysis for Avalo Therapeutics Inc yet.
Avalo Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporate…
Full company profileAvalo Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Avalo Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.15M | 27.8M | 18.3M | 6.75M | 6.70M | 5.40M | 18.1M | 1.92M | 441K | 59.0K | 0.00 |
| Gross Profit | -7.09M | 27.2M | 10.8M | 7.32M | 6.40M | 3.91M | 14.6M | 640K | 807K | 59.0K | - |
| Operating Income | -16.1M | 13.9M | -39.3M | -16.1M | -27.0M | -82.1M | -37.4M | -27.4M | -68.5M | -72.9M | -101M |
| EBITDA | -16.1M | 14.3M | -13.1M | -13.5M | -45.5M | -80.5M | -37.3M | -23.3M | -34.8M | -77.8M | -99.8M |
| Net Income | -16.5M | 11.9M | -40.1M | -16.1M | -63.5M | -84.4M | -41.7M | -31.5M | -35.1M | -78.3M | -99.9M |
| EPS | -5,372 | 1,823 | -3,317 | -810 | -2,489 | -2,331 | -1,063 | -114 | -3.26 | -5.84 | -1.81 |
| Balance Sheet | |||||||||||
| Total Assets | 5.77M | 43.1M | 70.3M | 36.1M | 43.8M | 80.2M | 33.4M | 21.0M | 151M | 116M | 481M |
| Total Liabilities | 5.56M | 15.3M | 49.3M | 15.1M | 19.2M | 57.1M | 44.3M | 13.7M | 17.7M | 33.4M | 44.9M |
| Shareholders' Equity | 207K | 27.9M | 20.9M | 21.0M | 24.6M | 23.1M | -10.9M | 7.30M | 133M | 83.0M | 437M |
| Cash & Short-term Investments | 5.13M | 2.47M | 10.6M | 11.2M | 18.9M | 54.6M | 13.2M | 7.42M | 135M | 98.3M | 393M |
| Total Debt | 2.35M | - | 15.4M | 156K | 426K | 33.3M | 19.9M | 537K | 568K | 2.43M | 153K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -14.6M | 12.5M | -3.13M | -19.1M | -40.5M | -70.9M | -26.8M | -30.7M | -49.1M | -51.5M | -63.1M |
| Capital Expenditure | 34.9K | 23.3K | 564K | 262K | 63.0K | 113K | 95.0K | 158K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -14.6M | 12.5M | -3.69M | -19.4M | -40.6M | -71.0M | -26.8M | -30.8M | -49.1M | -51.5M | -63.1M |
| Ratios | |||||||||||
| ROE | -7,957.0% | 42.6% | -191.6% | -76.6% | -258.5% | -365.5% | - | -431.9% | -26.4% | -94.2% | -22.9% |
| ROA | -285.5% | 27.5% | -57.0% | -44.5% | -145.1% | -105.2% | -124.8% | -150.3% | -23.3% | -67.2% | -20.8% |
| Net Profit Margin | -1,428.5% | 42.7% | -218.5% | -238.1% | -947.9% | -1,563.1% | -230.8% | -1,639.5% | -7,965.8% | -132,642.4% | - |
| Debt to Equity | 11.37x | - | 0.74x | 0.01x | 0.02x | 1.44x | - | 0.07x | 0.00x | 0.03x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Avalo Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 14.8M | 378 | - |
| 2021 | USD 32.9M | 909 | - |
| 2020 | - | - | - |
| 2019 | USD 1.08M | 54 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:240 on Dec 29, 2023.
Who owns Avalo Therapeutics Inc
- Insiders 2.90%
- Institutions 97.11%
- Public & others 0.00%
- Shares outstanding 57.8M
- Free float 44.3M
Top funds holding AVTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.68M | 3.11% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.58M | 2.93% | +2.69% | Oct 2026 |
| Fidelity Stock Selector Small Cap | 1.29M | 2.38% | +6.07% | Aug 2026 |
| iShares Russell 2000 ETF | 1.28M | 2.38% | 0.00% | Oct 2026 |
| HBM Healthcare Investments AG Ord | 668K | 1.24% | +206.42% | Sep 2026 |
| Fidelity Series Small Cap Opps | 648K | 1.20% | -6.80% | Aug 2026 |
| AB Small Cap Growth A | 582K | 1.08% | -2.85% | Sep 2026 |
| Fidelity Small Cap Index | 457K | 0.85% | 0.00% | Aug 2026 |
| Columbia Small Cap Growth Inst | 425K | 0.79% | 0.00% | Sep 2026 |
| Fidelity Small Cap Discovery | 406K | 0.75% | +5.60% | Aug 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 374K | 0.69% | 0.00% | Sep 2026 |
| Fidelity Series Small Cap Discovery | 365K | 0.68% | +10.30% | Aug 2026 |
| Fidelity Advisor Biotechnology I | 361K | 0.67% | 0.00% | Sep 2026 |
| BGF World Healthscience A2 | 316K | 0.59% | 0.00% | Jul 2026 |
| T. Rowe Price New Horizons | 306K | 0.57% | -11.03% | Sep 2026 |
| BlackRock Health Sciences Opps Inv A | 300K | 0.56% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 297K | 0.55% | +23.59% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 247K | 0.46% | +0.23% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 242K | 0.45% | -0.38% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 237K | 0.44% | +0.27% | Oct 2026 |
Top institutions holding AVTX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 5.10M | 9.46% | +77.12% | Jun 2026 |
| BlackRock Inc | 4.37M | 8.10% | +1,234.70% | Jun 2026 |
| Nantahala Capital Management, LLC | 3.72M | 6.91% | +201.58% | Jun 2026 |
| Deep Track Capital, LP | 3.61M | 6.69% | 0.00% | Jun 2026 |
| Caligan Partners LP | 3.16M | 5.87% | +93.51% | Jun 2026 |
| TCG Crossover Management, LLC | 3.02M | 5.60% | +308.61% | Jun 2026 |
| Affinity Asset Advisors, LLC | 2.90M | 5.38% | +116.28% | Jun 2026 |
| State Street Corp | 2.89M | 5.36% | +3,932.28% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 2.50M | 4.63% | +172.71% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.39M | 4.43% | +160.55% | Jun 2026 |
| venBio Select Advisor LLC | 2.33M | 4.33% | +65.48% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.26M | 4.20% | +214.61% | Jun 2026 |
| Bvf Inc | 2.08M | 3.85% | +27.11% | Jun 2026 |
| Bank of America Corp | 1.91M | 3.55% | +197.64% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.73M | 3.21% | +102.46% | Jun 2026 |
| Soleus Capital Management, L.P. | 1.65M | 3.07% | +274.45% | Jun 2026 |
| BRAIDWELL LP | 1.63M | 3.02% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.31M | 2.43% | 0.00% | Jun 2026 |
| AllianceBernstein L.P. | 1.26M | 2.34% | 0.00% | Jun 2026 |
| UBS Group AG | 1.21M | 2.24% | +5.87% | Jun 2026 |
Avalo Therapeutics Inc company profile
- Company name
- Avalo Therapeutics Inc
- Ticker
- AVTX.US
- Exchange
- USA Stocks
- Listed since
- Nov 13, 2015
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 33
- Fiscal year end
- December
- Address
- 1500 Liberty Ridge Drive, Wayne, PA, United States, 19087
- Phone
- 410 522 8707
- Website
- avalotx.com
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Avalo Therapeutics Inc management
10- Dr. Garry A. Neil M.D.President, CEO & Director · born 1954
- Dr. Mittie Doyle FACR, M.D.Chief Medical Officer · born 1965
- Mr. Taylor BoydChief Business Officer · born 1989
- Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory Board · born 1939
- Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory Board · born 1965
- Mr. Christopher Ryan Sullivan CPACFO & Head of Investor relations · born 1984
- Mr. Paul C. Varki J.D., M.P.HChief Legal Officer · born 1973
- Ms. Ashley IvanowiczSenior Vice President of Human Resources
- Dr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical Operations
- Ms. Jennifer RileyChief Strategy Officer · born 1975